Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) EPS (Basic) (2016 - 2026)

Cumberland Pharmaceuticals' EPS (Basic) history spans 16 years, with the latest figure at -$0.09 for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 35.71% to -$0.09 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.19, a 59.57% increase, with the full-year FY2025 number at -$0.19, up 58.7% from a year prior.
  • EPS (Basic) hit -$0.09 in Q4 2025 for Cumberland Pharmaceuticals, up from -$0.13 in the prior quarter.
  • Over the last five years, EPS (Basic) for CPIX hit a ceiling of $0.08 in Q2 2021 and a floor of -$0.44 in Q4 2023.
  • Historically, EPS (Basic) has averaged -$0.09 across 5 years, with a median of -$0.08 in 2024.
  • Biggest five-year swings in EPS (Basic): surged 233.33% in 2021 and later crashed 1500.0% in 2024.
  • Tracing CPIX's EPS (Basic) over 5 years: stood at -$0.26 in 2021, then soared by 34.62% to -$0.17 in 2022, then crashed by 158.82% to -$0.44 in 2023, then surged by 68.18% to -$0.14 in 2024, then skyrocketed by 35.71% to -$0.09 in 2025.
  • Business Quant data shows EPS (Basic) for CPIX at -$0.09 in Q4 2025, -$0.13 in Q3 2025, and -$0.05 in Q2 2025.